Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Melanoma × Hydroxychloroquine × Clear all

Phase

Status

Unknown 1 Recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 3 Pancreatic Neoplasms 2 Ovarian Neoplasms 2 Colorectal Neoplasms 2 Resectable Localized Prostate Cancer 1 Recurrence 1 Radiation-induced Oral Mucositis 1 Prostate Cancer Recurrent 1 Pancreatic Ductal Adenocarcinoma 1 Neoplasm, Residual 1 Neoplasm Metastasis 1 Nasopharyngeal Carcinoma 1 Melanoma 1 Lymphoma, Follicular 1 Lung Neoplasms 1 Carcinoma, Transitional Cell 1 Adenocarcinoma of Lung 1

Interventions

pembrolizumab 50 Nivolumab 49 Ipilimumab 27 Cyclophosphamide 15 Specimen Handling 10 Radiosurgery 10 Magnetic Resonance Spectroscopy 10 fludarabine 9 Opdualag 9 Biopsy 8 relatlimab 7 binimetinib 7 aldesleukin 7 Interleukin-2 7 Blood Specimen Collection 7 encorafenib 5 cemiplimab 5 Paclitaxel 5 Immunotherapy 5 Bevacizumab 5 toripalimab 4 atezolizumab 4 Temozolomide 4 CTLA-4 Antigen 4 trametinib 3 spartalizumab 3 lifileucel 3 fludarabine phosphate 3 dabrafenib 3 Surgical Procedures, Operative 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04464759 2025-07-08

LIMIT

Abramson Cancer Center at Penn Medicine

Phase 1/2 Recruiting

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡